Nuvalent, INC. (NUVL) — SEC Filings

Overview

Nuvalent, INC. (NUVL) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 8-K filed on Apr 7, 2026: Nuvalent, Inc. filed an 8-K on April 7, 2026, to report other events. The filing does not contain specific financial figures or new material agreements, but serves as a notification of events relevant to the company.

Sentiment Summary

Across 40 filings, the sentiment breakdown is: 2 bullish, 1 bearish, 36 neutral, 1 mixed. The dominant filing sentiment for Nuvalent, INC. is neutral.

Filing Type Overview

Nuvalent, INC. (NUVL) has filed 19 8-K, 6 10-Q, 2 DEF 14A, 2 10-K, 6 SC 13G/A, 4 SC 13G, 1 SC 13D/A with the SEC between Jan 2024 to Apr 2026.

Filings by Year

2026 · 2025 · 2024

Recent Filings (40)

• Nuvalent, Inc. Files 8-K for Other Events — 8-K · Apr 7, 2026 Risk: low
  Nuvalent, Inc. filed an 8-K on April 7, 2026, to report other events. The filing does not contain specific financial figures or new material agreements, but ser
• 8-K Filing — 8-K · Dec 16, 2025
• Nuvalent, Inc. Reports Director and Officer Changes — 8-K · Dec 10, 2025 Risk: medium
  Nuvalent, Inc. filed an 8-K on December 10, 2025, reporting changes effective December 9, 2025. The filing pertains to the departure of directors or certain off
• Nuvalent Enters Material Definitive Agreement — 8-K · Nov 20, 2025 Risk: medium
  Nuvalent, Inc. announced on November 18, 2025, that it has entered into a material definitive agreement. The company, incorporated in Delaware with its principa
• 8-K Filing — 8-K · Nov 17, 2025
• Nuvalent's Q3 Net Loss Widens 45% Amid Soaring R&D Costs — 10-Q · Oct 30, 2025 Risk: high
  Nuvalent, Inc. (NUVL) reported a significant increase in net loss for the three months ended September 30, 2025, reaching $122.4 million, up from $84.3 million
• Nuvalent Files 8-K for Other Events — 8-K · Sep 22, 2025 Risk: medium
  Nuvalent, Inc. filed an 8-K on September 22, 2025, to report other events. The filing does not contain specific details about the nature of these events, dollar
• Nuvalent's Q2 Loss Widens to $75.2M Amid R&D Surge — 10-Q · Aug 7, 2025 Risk: high
  Nuvalent, Inc. reported no revenue for the three and six months ended June 30, 2025, consistent with its clinical-stage status. The company's net loss for the t
• Nuvalent, Inc. Files 8-K — 8-K · Jul 21, 2025 Risk: low
  Nuvalent, Inc. filed an 8-K on July 21, 2025, reporting other events. The filing does not contain specific details about the nature of these events, dollar amou
• BioNTech to Acquire Nuvalent for $1.1 Billion — 8-K · Jun 24, 2025 Risk: medium
  Nuvalent, Inc. announced on June 24, 2025, that it has entered into a definitive agreement to be acquired by a subsidiary of BioNTech SE. The transaction is val
• Nuvalent Appoints New Director to Board — 8-K · Jun 20, 2025 Risk: low
  Nuvalent, Inc. announced on June 18, 2025, a change in its board of directors. Specifically, Dr. R. Brad Evans has been appointed as a Class II Director, effect
• Nuvalent Reports Director Departure, New CMO Appointment — 8-K · Jun 10, 2025 Risk: medium
  On June 9, 2025, Nuvalent, Inc. filed an 8-K to report changes in its board of directors and executive compensation. Specifically, the company announced the dep
• Nuvalent Files Q1 2025 10-Q, Details Drug Pipeline — 10-Q · May 8, 2025 Risk: medium
  Nuvalent, Inc. filed its 10-Q for the period ending March 31, 2025. The company reported on its financial position and business operations, including details on
• Nuvalent DEF 14A: Executive Compensation Details — DEF 14A · Apr 28, 2025 Risk: low
  Nuvalent, Inc. filed a DEF 14A on April 28, 2025, detailing executive compensation and board member information. Key individuals like Darlene Noci, Deborah Mill
• Nuvalent Appoints New Director to Board — 8-K · Apr 17, 2025 Risk: low
  Nuvalent, Inc. announced on April 11, 2025, a change in its board of directors. Dr. R. Brad Evans has been appointed as a Class II Director, effective immediate
• Nuvalent, Inc. Files 2024 10-K Annual Report — 10-K · Feb 27, 2025 Risk: medium
  Nuvalent, Inc. filed its 2024 10-K on February 27, 2025, reporting its financial performance for the fiscal year ending December 31, 2024. The company, based in
• Nuvalent Files 8-K: Other Events & Exhibits — 8-K · Jan 14, 2025 Risk: low
  Nuvalent, Inc. filed an 8-K on January 14, 2025, reporting an event on January 13, 2025. The filing is a current report under Section 13 or 15(d) of the Securit
• Nuvalent Files 8-K on Executive Changes and Financials — 8-K · Dec 9, 2024 Risk: low
  Nuvalent, Inc. filed an 8-K on December 9, 2024, reporting on the departure of directors or certain officers, election of directors, appointment of certain offi
• SC 13G/A Filing — SC 13G/A · Nov 14, 2024
• SC 13G/A Filing — SC 13G/A · Nov 14, 2024
• Nuvalent Files Q3 2024 10-Q — 10-Q · Nov 12, 2024 Risk: medium
  Nuvalent, Inc. filed its 10-Q for the period ending September 30, 2024. The company reported on its financial position and operations, including details on comm
• SC 13G Filing — SC 13G · Nov 8, 2024
• SC 13G Filing — SC 13G · Oct 24, 2024
• Nuvalent Enters Material Definitive Agreement — 8-K · Sep 17, 2024 Risk: medium
  Nuvalent, Inc. announced on September 16, 2024, that it entered into a material definitive agreement. The company also reported other events and filed financial
• Nuvalent Files 8-K: Other Events & Financials — 8-K · Sep 16, 2024 Risk: low
  Nuvalent, Inc. filed an 8-K on September 16, 2024, reporting on other events and financial statements. The filing date for the report is September 14, 2024. The
• Nuvalent Files 10-Q: Financials and Equity Details — 10-Q · Aug 8, 2024 Risk: medium
  Nuvalent, Inc. filed its 10-Q for the period ending June 30, 2024. The filing details the company's financial position, including common stock and retained earn
• Nuvalent Appoints Dr. Arvind Sood as Chief Medical Officer — 8-K · Jul 22, 2024 Risk: medium
  On July 22, 2024, Nuvalent, Inc. announced the appointment of Dr. Arvind Sood as Chief Medical Officer. Dr. Sood brings extensive experience in oncology drug de
• Nuvalent Files 8-K on Shareholder Vote Matters — 8-K · Jun 14, 2024 Risk: low
  Nuvalent, Inc. filed an 8-K on June 14, 2024, reporting on matters submitted to a vote of security holders on June 12, 2024. The filing details the company's co
• Nuvalent Appoints New Chief Medical Officer — 8-K · May 16, 2024 Risk: medium
  On May 16, 2024, Nuvalent, Inc. announced the appointment of Dr. R. Christopher L. Smith as Chief Medical Officer, effective May 20, 2024. Dr. Smith brings exte
• SC 13G/A Filing — SC 13G/A · May 15, 2024
• Nuvalent, Inc. Files 10-Q for Period Ending March 31, 2024 — 10-Q · May 9, 2024 Risk: low
  Nuvalent, Inc. (NUVL) filed a Quarterly Report (10-Q) with the SEC on May 9, 2024. Nuvalent, Inc. filed a 10-Q report for the period ending March 31, 2024. The
• Nuvalent, Inc. Announces 2024 Annual Meeting of Stockholders on June 12, 2024 — DEF 14A · Apr 26, 2024 Risk: low
  Nuvalent, Inc. (NUVL) filed a Proxy Statement (DEF 14A) with the SEC on April 26, 2024. Nuvalent, Inc. will hold its 2024 Annual Meeting of Stockholders virtual
• Bain Capital Life Sciences Amends Nuvalent Stake — SC 13D/A · Mar 29, 2024 Risk: medium
  On March 29, 2024, Bain Capital Life Sciences Fund II, L.P. and BCIP Life Sciences Associates, LP filed an amendment (Amendment No. 3) to their Schedule 13D reg
• Nuvalent, Inc. Files 2023 Annual Report on Form 10-K — 10-K · Feb 27, 2024 Risk: medium
  Nuvalent, Inc. (NUVL) filed a Annual Report (10-K) with the SEC on February 27, 2024. Nuvalent, Inc. filed its 2023 Form 10-K on February 27, 2024, reporting on
• SC 13G/A Filing — SC 13G/A · Feb 14, 2024
• SC 13G Filing — SC 13G · Feb 13, 2024
• Deerfield Management Updates Nuvalent Stake in SC 13G/A Filing — SC 13G/A · Feb 12, 2024 Risk: low
  Deerfield Management Company, L.P. and its affiliated entities, including Deerfield Healthcare Innovations Fund, L.P., filed an amended SC 13G/A on February 12,
• FMR LLC & Abigail Johnson Hold 14.942% Stake in Nuvalent Inc. — SC 13G/A · Feb 9, 2024 Risk: low
  FMR LLC, a major investment firm, and its principal owner, Abigail P. Johnson, have filed an amended Schedule 13G/A for Nuvalent, Inc. (NASDAQ: NUVL). As of Feb
• Nuvalent 8-K Signals Update on Financial Condition — 8-K · Jan 9, 2024
  Nuvalent, Inc. filed an 8-K on January 9, 2024, reporting an event that occurred on January 8, 2024, related to 'Results of Operations and Financial Condition'
• Perceptive Advisors Discloses 5.0% Stake in Nuvalent (NUVL) — SC 13G · Jan 2, 2024
  Perceptive Advisors LLC, a Delaware-based investment manager, has disclosed a significant stake in Nuvalent, Inc. (NASDAQ: NUVL), a pharmaceutical company. As o

Risk Profile

Risk Assessment: Of NUVL's 29 recent filings, 2 were flagged as high-risk, 14 as medium-risk, and 13 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.

Financial Highlights

Key financial metrics from Nuvalent, INC.'s most recent 10-Q filing (Oct 30, 2025):

• Revenue: $0
• Net Income: -$122.4M
• EPS: N/A
• Debt-to-Equity: 0.16
• Cash Position: $115.8M
• Operating Margin: N/A
• Total Assets: $979.9M
• Total Debt: $134.5M

Key Executives

• Dr. R. Brad Evans
• Dr. David R. Parkinson
• Darlene Noci
• Deborah Miller
• Alexandra Balcom
• James R. Porter
• Dr. Arvind Sood
• Dr. R. Christopher L. Smith
• Emily Drabant Conley, Ph.D.
• Sapna Srivastava, Ph.D.
• Cameron Wheeler, Ph.D.
• Flynn James E
• Abigail P. Johnson

Industry Context

Nuvalent operates in the highly competitive and capital-intensive biotechnology sector, focusing on developing novel therapies for cancer. The industry is characterized by long development cycles, high R&D costs, and significant regulatory hurdles. Success hinges on innovation, clinical trial outcomes, and securing substantial funding to navigate these challenges.

Top Tags

10-Q (4) · financials (4) · 8-K (3) · corporate-governance (3) · filing (3) · oncology (3) · biotech (3) · institutional-ownership (3) · regulatory-filing (2) · management-change (2)

Key Numbers

• SEC File Number: 001-40671 — Identifies Nuvalent's filings with the SEC.
• I.R.S. Employer Identification No.: 81-5112298 — Tax identification number for Nuvalent, Inc.
• Net Loss for Q3 2025: $122.4M — Increased 45.2% from $84.3M in Q3 2024
• Net Loss for Nine Months Ended Sep 30, 2025: $306.7M — Increased 64.9% from $186.0M in the prior year period
• Research and Development Expenses for Q3 2025: $83.8M — Increased 38.5% from $60.5M in Q3 2024
• General and Administrative Expenses for Q3 2025: $28.8M — Increased 83.4% from $15.7M in Q3 2024
• Cash and Cash Equivalents as of Sep 30, 2025: $115.8M — Decreased from $145.7M at Dec 31, 2024
• Marketable Securities as of Sep 30, 2025: $827.4M — Decreased from $972.6M at Dec 31, 2024
• Related Party Revenue Share Liability as of Sep 30, 2025: $45.2M — Increased from $17.9M at Dec 31, 2024
• Class A Common Stock Shares Outstanding: 67,271,461 — As of October 23, 2025
• Revenue: $0 — Nuvalent reported no revenue for Q2 2025, consistent with its clinical-stage status.
• Net Loss (Q2 2025): -$75.2M — Increased from -$59.3M in Q2 2024, reflecting higher R&D spending.
• Net Loss (YTD 2025): -$146.5M — Increased from -$112.1M in YTD 2024, indicating accelerated operational costs.
• R&D Expense (Q2 2025): $65.8M — Increased from $50.7M in Q2 2024, driven by advancing clinical programs.
• Cash, Cash Equivalents, and Marketable Securities: $600.0M — As of June 30, 2025, providing liquidity for ongoing operations and drug development.

Forward-Looking Statements

• {"claim":"Deerfield Management will maintain a significant stake in Nuvalent, Inc. throughout 2024.","entity":"Deerfield Management Company, L.P.","targetDate":"2024-12-31","confidence":"medium"}
• {"claim":"FMR LLC will maintain a significant, passive stake in Nuvalent, Inc. for the foreseeable future.","entity":"FMR LLC","targetDate":"2025-02-09","confidence":"high"}

Related Companies

NUVAL · BNTX

Frequently Asked Questions